Terapevticheskii arkhiv · 1999
[Choice of anti-helicobacter treatment of gastroduodenal ulcer associated with helicobater pylori].
Клиническое исследованиеСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Starostin B D
Аннотация
AIM: Choice of optimal antihelicobacter (AH) treatment of ulcer.
MATERIALS AND METHODS: 249 outpatients with duodenal ulcer associated with Helicobacter pylori entered a blind multicenter controlled trial. The patients were given one of the following drugs: metronidazole, tonidazol, amoxicilline, clarithromycin, rovamycin, omeprazole, azitromycin.
RESULTS: Of all the drugs used, rovamycin appeared preferable as it has high AH activity, is safe and cost-effective.
CONCLUSION: Rovamycin has a high AH activity and can be applied for treatment of diseases associated with Helicobacter pylori as a drug of choice.
MATERIALS AND METHODS: 249 outpatients with duodenal ulcer associated with Helicobacter pylori entered a blind multicenter controlled trial. The patients were given one of the following drugs: metronidazole, tonidazol, amoxicilline, clarithromycin, rovamycin, omeprazole, azitromycin.
RESULTS: Of all the drugs used, rovamycin appeared preferable as it has high AH activity, is safe and cost-effective.
CONCLUSION: Rovamycin has a high AH activity and can be applied for treatment of diseases associated with Helicobacter pylori as a drug of choice.